

**CHILDREN'S CANCER THERAPY  
DEVELOPMENT INSTITUTE**

**CONSOLIDATED FINANCIAL STATEMENTS  
AND SUPPLEMENTARY FINANCIAL INFORMATION**

**Year Ended June 30, 2024**



**KERN ▲ THOMPSON**  
CERTIFIED PUBLIC ACCOUNTANTS

**CHILDREN'S CANCER THERAPY DEVELOPMENT INSTITUTE**

**CONSOLIDATED FINANCIAL STATEMENTS**

**Year Ended June 30, 2024**

**TABLE OF CONTENTS**

	<b><u>Page</u></b>
<b>INDEPENDENT AUDITOR'S REPORT</b>	1-2
<b>FINANCIAL STATEMENTS</b>	
Consolidated Statement of Financial Position	3
Consolidated Statement of Activities	4
Consolidated Statement of Functional Expenses	5
Consolidated Statement of Cash Flows	6
Notes to Consolidated Financial Statements	7-13
<b>SUPPLEMENTARY FINANCIAL INFORMATION</b>	
Consolidating Statement of Financial Position	14
Consolidating Statement of Activities	15

**INDEPENDENT AUDITOR'S REPORT**

To the Board of Directors  
Children's Cancer Therapy Development Institute  
Hillsboro, Oregon

***Opinion***

We have audited the accompanying consolidated financial statements of Children's Cancer Therapy Development Institute (a nonprofit organization), which comprise the statement of financial position as of June 30, 2024, and the related statements of activities, functional expenses, and cash flows for the year then ended, and the related notes to the financial statements.

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of Children's Cancer Therapy Development Institute as of June 30, 2024, and the changes in net assets and its cash flows for the year then ended in accordance with accounting principles generally accepted in the United States of America.

***Basis for Opinion***

We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of Children's Cancer Therapy Development Institute and to meet our other ethical responsibilities in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

***Responsibilities of Management for the Financial Statements***

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about Children's Cancer Therapy Development Institute's ability to continue as a going concern within one year after the date that the financial statements are available to be issued.

***Auditor's Responsibilities for the Audit of the Financial Statements***

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with generally accepted auditing standards will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements, including omissions, are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

To the Board of Directors  
Children's Cancer Therapy Development Institute

In performing an audit in accordance with generally accepted auditing standards, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of Children's Cancer Therapy Development Institute's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about Children's Cancer Therapy Development Institute's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control related matters that we identified during the audit.

***Report on Summarized Comparative Information***

We have previously audited Children's Cancer Therapy Development Institute's 2023 consolidated financial statements, and we expressed an unmodified opinion on those audited financial statements in our report dated October 31, 2023. In our opinion, the summarized comparative information presented herein as of and for the year ended June 30, 2023, is consistent, in all material respects, with the audited financial statements from which it has been derived.

***Report on Supplementary Information***

Our audit was conducted for the purpose of forming an opinion on the financial statements as a whole. The consolidating statement of financial position and the consolidating statement of activities on pages 14 and 15 are presented for purposes of additional analysis and are not a required part of the financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the financial statements. The information has been subjected to the auditing procedures applied in the audit of the financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the financial statements or to the financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the information is fairly stated in all material respects in relation to the financial statements as a whole.



Portland, Oregon  
November 5, 2024

**CHILDREN'S CANCER THERAPY DEVELOPMENT INSTITUTE**

**CONSOLIDATED STATEMENT OF FINANCIAL POSITION**

**June 30, 2024**

(With Comparative Amounts as of June 30, 2023)

**ASSETS**

	<b>2024</b>	<b>2023</b>
Cash and cash equivalents	\$ 500,017	\$ 909,184
Investments	-	243,637
Grants and contributions receivable	373,229	391,208
Prepaid expenses and deposits	129,612	128,282
Right of Use asset	677,360	798,860
Property and equipment, net	1,590,875	721,160
<b>Total assets</b>	<b>\$ 3,271,093</b>	<b>\$ 3,192,331</b>

**LIABILITIES AND NET ASSETS**

Accounts payable and accrued expenses	\$ 182,082	\$ 133,325
Lease liability	691,092	802,615
<b>Total liabilities</b>	<b>873,174</b>	<b>935,940</b>
<b>Net assets</b>		
Without donor restrictions		
Available for operations	295,847	803,423
Invested in property, plant and equipment	1,590,875	721,160
Total without donor restrictions	1,886,722	1,524,583
With donor restrictions	511,197	731,808
<b>Total net assets</b>	<b>2,397,919</b>	<b>2,256,391</b>
<b>Total liabilities and net assets</b>	<b>\$ 3,271,093</b>	<b>\$ 3,192,331</b>

See notes to the consolidated financial statements.

**CHILDREN'S CANCER THERAPY DEVELOPMENT INSTITUTE**

**CONSOLIDATED STATEMENT OF ACTIVITIES**

**Year Ended June 30, 2024**

(With Comparative Totals for the Year Ended June 30, 2023)

	<b>Without Donor Restrictions</b>	<b>With Donor Restrictions</b>	<b>Total</b>	
			<b>2024</b>	<b>2023</b>
<b>Grants, contributions and other support</b>				
Individual and corporate contributions	\$ 263,908	\$ 247,234	\$ 511,142	\$ 695,618
Foundation and trust grants	88,700	655,952	744,652	1,102,911
Government contracts and grants	-	1,453,355	1,453,355	209,810
In-kind contributions	-	-	-	44,400
Program revenue	133,703	-	133,703	132,889
Investment income	27,039	-	27,039	5,606
Other	26,720	1,049	27,769	3,876
	540,070	2,357,590	2,897,660	2,195,110
Net assets released from restrictions	2,578,201	(2,578,201)	-	-
<b>Total grants, contributions and other support</b>	<b>3,118,271</b>	<b>(220,611)</b>	<b>2,897,660</b>	<b>2,195,110</b>
<b>Expenses</b>				
Program services				
Research	2,119,269	-	2,119,269	2,026,539
Education	10,468	-	10,468	8,880
Artisan	2,107	-	2,107	4,302
Total program expenses	2,131,844	-	2,131,844	2,039,721
Supporting services				
Management and general	418,312	-	418,312	292,434
Fundraising	205,976	-	205,976	226,315
<b>Total expenses</b>	<b>2,756,132</b>	<b>-</b>	<b>2,756,132</b>	<b>2,558,470</b>
<b>Change in net assets</b>	<b>362,139</b>	<b>(220,611)</b>	<b>141,528</b>	<b>(363,360)</b>
Net assets, beginning of year	1,524,583	731,808	2,256,391	2,619,751
<b>Net assets, end of year</b>	<b>\$ 1,886,722</b>	<b>\$ 511,197</b>	<b>\$ 2,397,919</b>	<b>\$ 2,256,391</b>

See notes to the consolidated financial statements.

**CHILDREN'S CANCER THERAPY DEVELOPMENT INSTITUTE**

**CONSOLIDATED STATEMENT OF FUNCTIONAL EXPENSES**

**Year Ended June 30, 2024**

(With Comparative Totals for the Year Ended June 30, 2023)

	<u>PROGRAM SERVICES</u>				<u>SUPPORTING SERVICES</u>			<u>Total</u>	
	<u>Research</u>	<u>Education</u>	<u>Artisan</u>	<u>Total Program</u>	<u>Management and General</u>	<u>Fundraising</u>	<u>2024</u>	<u>2023</u>	
Salaries, payroll taxes and benefits	\$ 879,153	\$ 46	\$ -	\$ 879,199	\$ 288,399	\$ 117,194	\$ 1,284,792	\$ 1,114,665	
Professional fees	367,446	7	650	368,103	90,670	37,030	495,803	542,023	
Software, supplies and equipment	383,673	80	1,457	385,210	3,738	9,835	398,783	452,498	
Occupancy and utilities	185,421	763	-	186,184	30,481	15,009	231,674	190,402	
Depreciation and amortization	222,262	-	-	222,262	-	-	222,262	135,455	
Printing, postage and office supplies	22,732	35	-	22,767	1,882	5,071	29,720	50,569	
Travel and related costs	39,754	265	-	40,019	104	3,518	43,641	42,067	
Licenses, dues and fees	11,509	21	-	11,530	1,564	3,692	16,786	11,882	
Miscellaneous	-	-	-	-	-	-	-	109	
Marketing and communications	2,549	9,227	-	11,776	228	14,162	26,166	11,988	
Insurance	4,770	24	-	4,794	1,246	465	6,505	6,812	
<b>Total expenses</b>	<b><u>\$ 2,119,269</u></b>	<b><u>\$ 10,468</u></b>	<b><u>\$ 2,107</u></b>	<b><u>\$ 2,131,844</u></b>	<b><u>\$ 418,312</u></b>	<b><u>\$ 205,976</u></b>	<b><u>\$ 2,756,132</u></b>	<b><u>\$ 2,558,470</u></b>	

See notes to the consolidated financial statements.

**CHILDREN'S CANCER THERAPY DEVELOPMENT INSTITUTE**

**CONSOLIDATED STATEMENT OF CASH FLOWS**

**Year Ended June 30, 2024**

(With Comparative Totals for the Year Ended June 30, 2023)

	<b>2024</b>	<b>2023</b>
<b>Cash flows from operating activities:</b>		
Change in net assets	\$ 141,528	\$ (363,360)
Adjustments to reconcile change in net assets to net cash provided by (used in) operating activities:		
Depreciation	222,262	135,455
Realized and unrealized (gain) loss on investment	-	(6,412)
Change in measurement of leases	9,977	938
Changes in assets and liabilities:		
Grants and contributions receivable	17,979	(22,333)
Prepaid expenses and deposits	(1,330)	(38,727)
Accounts payable and accrued expenses	48,757	22,452
<b>Net cash provided by (used in) operating activities</b>	<b>439,173</b>	<b>(271,987)</b>
<b>Cash flows from investing activities:</b>		
Purchase of property and equipment	(1,091,977)	(653,268)
Purchase of investments	-	(540,662)
Proceeds from sale of investments	243,637	568,238
Reinvestment of earnings	-	(11,767)
<b>Net cash provided by (used in) investing activities</b>	<b>(848,340)</b>	<b>(637,459)</b>
<b>Net change in cash and cash equivalents</b>	<b>(409,167)</b>	<b>(909,446)</b>
Cash and cash equivalents, beginning of year	909,184	1,818,630
<b>Cash and cash equivalents, end of year</b>	<b>\$ 500,017</b>	<b>\$ 909,184</b>

See notes to financial statements.



## CHILDREN'S CANCER THERAPY DEVELOPMENT INSTITUTE

### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

June 30, 2024

#### NOTE A – DESCRIPTION OF ORGANIZATION

Children's Cancer Therapy Development Institute, (cc-TDI or the Organization) is a non-profit corporation in Portland, Oregon, created to translate scientific discovery into clinical trials by understanding and proving new disease-specific treatment options for children with cancer. cc-TDI was created with one aim: to make childhood cancer universally survivable, regardless of diagnosis. cc-TDI's research team explores and tests state-of-the-art treatment options for the most urgent issues facing children with cancer. cc-TDI performs basic science and translational research in an industrial modern lab site. By proving these methods in the laboratory, cc-TDI delivers smart, hope-filled discoveries to be prioritized in clinical trials.

#### NOTE B – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

##### Basis of Accounting

cc-TDI prepares its consolidated financial statements on the accrual basis of accounting; consequently, certain revenues are reflected in the accounts in the period in which they are considered earned, rather than received, and expenses are recorded when incurred, rather than when paid. Assets and liabilities are presented on the basis of historical cost rather than estimated current values and amounts.

##### Financial Statement Presentation

The Organization reports information regarding its financial position and activities according to two classes of net assets: without donor restrictions and with donor restrictions. Accordingly, the net assets of the Organization and changes therein are classified and reported as follows:

- **Net Assets Without Donor Restrictions** – Net assets that are not subject to donor-imposed stipulations. The Board of Directors may designate net assets without donor restrictions for specific purposes.
- **Net Assets With Donor Restrictions** – Net assets subject to donor-imposed stipulations that will be met either by actions of the Organization and/or the passage of time, or net assets with donor restrictions that are not subject to appropriation or expenditure.

Expenses are reported as a decrease in net assets without donor restrictions. Gains and losses are reported as increases or decreases in net assets without donor restrictions unless their use is restricted by explicit donor stipulation or by law. Expiration of net assets with donor restrictions (i.e., the donor-stipulated purpose has been fulfilled and/or the stipulated time period has elapsed) are reported as net assets released from restrictions.

##### Basis of Consolidation

The accompanying consolidated financial statements include the accounts of Artisan Biopharma, Inc. (a C corporation with a June 30 year-end). Children's Cancer Therapy Development Institute owns 100% of the outstanding common stock of Artisan Biopharma, Inc. The results of operations of Artisan Biopharma, Inc. have been consolidated with those of Children's Cancer Therapy Development Institute. All inter-company accounts and transactions have been eliminated.

**CHILDREN'S CANCER THERAPY DEVELOPMENT INSTITUTE**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)**

**June 30, 2024**

**NOTE B – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)**

**Contributions**

Contributions are recognized when the donor makes a promise to give to the Organization that is, in substance, unconditional. Contributions with donor restrictions are reported as increases in net assets with donor restrictions depending on the nature of the restrictions. Otherwise, when a restriction expires, net assets with donor restrictions are reclassified to net assets without donor restrictions. Conditional promises to give are not recognized until the conditions on which they depend are substantially met. An allowance for uncollectible contributions receivable may be provided based upon management's judgment, including such factors as prior collection history, the type of contribution, and the nature of the fund-raising activity. Management has determined that no allowance for uncollectible accounts is necessary at June 30, 2024.

**Revenue Recognition**

With regard to revenues from all sources, the Organization evaluates whether each transfer of assets is (1) an exchange (reciprocal) transaction in which a resource provider receives commensurate value in return for the assets transferred, or (2) a nonreciprocal transfer (a contribution or a grant), where no value is exchanged.

- *Exchange Transactions* – If the transfer of assets is determined to be an exchange transaction, the Organization recognizes revenue when or as it satisfies the required performance obligations and transfers the promised good or service to a customer, and when the customer obtains control of that good or service.
- *Contributions and Grants* – If the transfer of assets is determined to be a contribution, the Organization evaluates whether the contribution is conditional based upon whether the agreement includes both (1) a barrier that must be overcome to be entitled to the funds and (2) either a right of return of assets transferred or a release of a promisor's obligation to transfer assets.

**Estimates**

The preparation of consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates.

**Cash and Cash Equivalents**

cc-TDI considers all highly liquid investments with an initial maturity of three months or less to be cash equivalents. cc-TDI maintains its cash in bank deposit accounts which, at times, may exceed federally insured limits. cc-TDI has not experienced any losses in such accounts, and believes it is not exposed to any significant credit risk on cash and cash equivalents. At June 30, 2024, all cash held was FDIC insured.

**CHILDREN'S CANCER THERAPY DEVELOPMENT INSTITUTE**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)**

**June 30, 2024**

**NOTE B – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)**

**Property and Equipment**

Acquisitions of property and equipment in excess of \$5,000 are capitalized. Property and equipment are carried at cost or, if donated, at the approximate fair value at the date of donation. Depreciation is computed on a straight-line basis over the useful lives of the assets generally as follows:

Building and improvements	40 years
Furniture, fixtures, and equipment	5 to 7 years
Computer software	3 years

**Income Taxes**

cc-TDI has been approved as a tax exempt organization under the Internal Revenue Code Section 501(c)(3) and applicable state laws. cc-TDI's wholly-owned subsidiary, Artisan Biopharma, is a taxable corporation and, therefore, a provision for any income taxes would be provided in the consolidated statement of activities. cc-TDI does not believe it has unrelated trade or business income in excess of \$1,000.

**Functional Allocation of Expenses**

The costs of providing the programs and supporting services have been summarized in the Statement of Activities. Directly identifiable expenses are charged to programs and supporting services when incurred. Certain costs, including office expense, occupancy, leases and utilities have been allocated among the programs and supporting services benefited based primarily on estimates of time and effort.

**Leases**

The Organization determines if an arrangement is a lease or contains a lease at inception of a contract. A contract is determined to be or contain a lease if the contract conveys the right to control the use of identified property, plant, or equipment (an identified asset) in exchange for consideration. The Organization determines these assets are leased because the Organization has the right to obtain substantially all of the economic benefit from and the right to direct the use of the identified asset. Assets in which the supplier or lessor has the practical ability and right to substitute alternative assets for the identified asset and would benefit economically for the exercise of the right to substitute the asset are not considered to be or contain a lease because the Organization determines it does not have the right to contract and direct the use of the identified asset.

In evaluating its contracts, the Organization separately identifies lease and nonlease components, such as fixed common area and other fixed maintenance costs, in calculating the Right of Use (ROU) assets and lease liabilities for its office buildings. Leases result in the recognition of ROU assets and lease liabilities on the statement of financial position. ROU assets represent the right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make lease payments arising from the lease, measured on a discounted basis. The Organization determines lease classification as operating or finance at the lease commencement date. At lease inception, the lease liability is measured at the present value of the lease payments over the lease term. The ROU asset equals the lease liability adjusted for any initial direct costs, prepaid or deferred rent, and lease incentives.

**CHILDREN'S CANCER THERAPY DEVELOPMENT INSTITUTE**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)**

**June 30, 2024**

**NOTE B – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)**

**Leases (Continued)**

The Organization uses a risk free discount rate for its leased office space. The lease term may include options to extend or to terminate the lease that the Organization is reasonably certain to exercise. Lease expense is generally recognized on a straight-line basis over the lease term. The Organization has elected not to record leases with an initial term of 12 months or less on the statement of financial position.

**Prior Year Summarized Financial Information**

The consolidated financial statements include certain prior-year summarized comparative information in total but not by net asset class or natural expense classification by function. Such information does not include sufficient detail to constitute a presentation in conformity with generally accepted accounting principles. Accordingly, such information should be read in conjunction with cc-TDI's consolidated financial statements for the year ended June 30, 2023, from which the summarized information was derived.

**NOTE C – PROPERTY AND EQUIPMENT**

Property and equipment consist of the following at June 30, 2024:

Building and improvements	\$	595,891
Furniture, fixtures, and equipment		1,855,872
		<u>2,451,763</u>
Less accumulated depreciation and amortization		(860,888)
	\$	<u><u>1,590,875</u></u>

Depreciation expense for the year ended June 30, 2024 was \$222,262.

**NOTE D – CONDITIONAL PROMISES TO GIVE**

A portion of the Organization's revenue is derived from cost-reimbursable federal contracts and other grants, which are conditioned upon certain performance requirements and/or the incurrence of allowable qualifying expenses. Amounts received are recognized as revenue when the Organization has incurred expenditures in compliance with specific contract or grant provisions. Amounts received prior to incurring qualifying expenditures are reported as refundable advances in the statement of financial position. As of June 30, 2024, the Organization has conditional grants as follows:

National Institute of Health (NIH)	\$	213,865
Cancer Research United Kingdom (CRUK)		513,000
	\$	<u><u>726,865</u></u>

The CRUK grant award was made in British Pounds and is payable in British Pounds. The \$513,000 remaining conditional promise as of June 30, 2024 is an estimate based on the current pound to US Dollar exchange rate.

**CHILDREN’S CANCER THERAPY DEVELOPMENT INSTITUTE**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)**

**June 30, 2024**

**NOTE D – CONDITIONAL PROMISES TO GIVE (CONTINUED)**

In addition, the Organization has agreed to the terms of several sponsored cooperative research agreements, the proceeds of which cannot be readily estimated as payments are conditioned upon achieving certain milestones beyond the Organization’s control. The proceeds will be recorded at the time the specified milestones have been achieved.

**NOTE E – NET ASSETS WITH DONOR RESTRICTIONS**

Net assets with donor restrictions as of June 30, 2024, primarily consist of support for the following funded projects:

Subject to purpose restrictions		
Cancer biobank & registry	\$	26,326
Epithelioid Sarcoma		2,880
Ewing Sarcoma		5,000
Hepatoblastoma		38,942
Medulloblastoma		27,185
Osteosarcoma		2,255
Neuroblastoma		25,267
State equipment grant		89,974
Research - Artisan collaboration		23,076
Rhabdomyosarcoma		115,024
Sclerosing epithelioid fibrosarcoma		<u>155,268</u>
Total net assets with donor restrictions	\$	<u><u>511,197</u></u>

**NOTE F – RETIREMENT PLAN**

cc-TDI offers a tax-deferred 401(k) plan (the Plan) for all eligible employees. cc-TDI provides a safe-harbor contribution of 3% of employee compensation plus a 4% employee contribution match. The Organization can elect to provide additional profit-sharing contributions in excess of the 3% safe-harbor amount. Employer contributions to the Plan for the year ended June 30, 2024, were \$62,464.

**CHILDREN'S CANCER THERAPY DEVELOPMENT INSTITUTE**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)**

**June 30, 2024**

**NOTE G – LEASE COMMITMENTS**

The Organization has a lease for office space that expires in August, 2029. The lease includes an escalating fee schedule of about three percent per year.

Annual lease cost	\$ <u>140,099</u>
Cash paid for amounts included in the measurement of lease liabilities:	
Operating cash flows from leases	\$ <u>130,122</u>
Weighted-average remaining lease term	5 years
Weighted-average discount rate	2.50%
<u>Year Ending June 30,</u>	<u>Operating Leases</u>
2025	\$ 134,024
2026	138,048
2027	142,192
2028	146,456
2029	150,848
2030	<u>25,640</u>
Total future undiscounted lease payments	737,208
Less present value discount	<u>(46,116)</u>
Lease liability	<u>\$ <u>691,092</u></u>

**NOTE H – RELATED PARTY TRANSACTIONS**

The Organization's Science Director is both a voting board member as well as a compensated employee. He was compensated \$311,457 along with other employee benefits of \$27,042 during the year ending June 30, 2024.

**CHILDREN'S CANCER THERAPY DEVELOPMENT INSTITUTE**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)**

**June 30, 2024**

**NOTE I – LIQUIDITY**

The following represents the Organization's financial assets available to meet cash needs for general expenditures within one year of June 30, 2024:

Financial assets at year-end	
Cash and cash equivalents	\$ 500,017
Grants and contribution receivables	<u>373,229</u>
 Total financial assets	 \$ <u>873,246</u>

The Organization receives significant contributions and promises to give that are donor restricted, and considers contributions restricted for programs which are ongoing, major, and central to its annual operations to be available to meet cash needs for general expenditures.

The Organization manages its liquidity and reserves following three guiding principles: operating within a prudent range of financial soundness and stability, maintaining adequate liquid assets to fund near-term operating needs, and maintaining sufficient reserves to provide reasonable assurance that long-term obligations will be discharged. To achieve these targets, the Organization forecasts its future cash flows, monitors its liquidity monthly and monitors its reserves annually. During the fiscal year ended June 30, 2024, the level of liquidity and reserves were managed within the policy requirements.

**NOTE J – SUBSEQUENT EVENTS**

Subsequent events have been evaluated through November 5, 2024, which is the date the consolidated financial statements were available to be issued.

**SUPPLEMENTARY FINANCIAL INFORMATION**



**CHILDREN'S CANCER THERAPY DEVELOPMENT INSTITUTE**  
**CONSOLIDATING STATEMENT OF FINANCIAL POSITION**

June 30, 2024

**ASSETS**

	<u>Nonprofit</u>	<u>Subsidiary</u>	<u>Eliminations</u>	<u>Consolidated</u>
Cash and cash equivalents	\$ 493,209	\$ 6,808	\$ -	\$ 500,017
Investments	75,731	-	(75,731)	-
Contributions and grants receivable	373,229	-	-	373,229
Prepaid expenses and deposits	129,612	-	-	129,612
Right of Use asset	677,360	-	-	677,360
Property and equipment, net	1,590,875	-	-	1,590,875
<b>Total assets</b>	<b>\$ 3,340,016</b>	<b>\$ 6,808</b>	<b>\$ (75,731)</b>	<b>\$ 3,271,093</b>

**LIABILITIES AND NET ASSETS**

Accounts payable and accrued expenses	\$ 182,082	\$ -	\$ -	\$ 182,082
Lease liability	691,092	-	-	691,092
<b>Total liabilities</b>	<b>873,174</b>	<b>-</b>	<b>-</b>	<b>873,174</b>
<b>Net assets</b>				
Common stock	-	75,731	(75,731)	-
Without donor restrictions (deficit)	1,955,645	(68,923)	-	1,886,722
With donor restrictions	511,197	-	-	511,197
<b>Total net assets</b>	<b>2,466,842</b>	<b>6,808</b>	<b>(75,731)</b>	<b>2,397,919</b>
<b>Total liabilities and net assets</b>	<b>\$ 3,340,016</b>	<b>\$ 6,808</b>	<b>\$ (75,731)</b>	<b>\$ 3,271,093</b>

The accompanying notes and independent auditor's report should be read in conjunction with the supplemental schedules.

**CHILDREN'S CANCER THERAPY DEVELOPMENT INSTITUTE**

**CONSOLIDATING STATEMENT OF ACTIVITIES**

**Year Ended June 30, 2024**

	<b>Nonprofit</b>	<b>Subsidiary</b>	<b>Eliminations</b>	<b>Consolidated</b>
<b>Public support and related revenues</b>				
Individual and corporate contributions	\$ 511,142	\$ -	\$ -	\$ 511,142
Foundation and trust grants	744,652	-	-	744,652
Government contracts and grants	1,453,355	-	-	1,453,355
Program revenue	133,703	-	-	133,703
Investment income	27,039	-	-	27,039
Other	27,769	-	-	27,769
<b>Total grants, contributions and other support</b>	<b>2,897,660</b>	<b>-</b>	<b>-</b>	<b>2,897,660</b>
 <b>Expenses</b>				
Program services				
Research	2,119,270	-	-	2,119,270
Education	10,467	-	-	10,467
Artisan	-	2,107	-	2,107
Total program expenses	2,129,737	2,107	-	2,131,844
Supporting services				
Management and general	418,312	-	-	418,312
Fundraising	205,976	-	-	205,976
<b>Total expenses</b>	<b>2,754,025</b>	<b>2,107</b>	<b>-</b>	<b>2,756,132</b>
 <b>Change in net assets</b>	143,635	(2,107)	-	141,528
Net assets, beginning of year	2,323,207	(66,816)	-	2,256,391
<b>Net assets, end of year</b>	<b>\$ 2,466,842</b>	<b>\$ (68,923)</b>	<b>\$ -</b>	<b>\$ 2,397,919</b>

The accompanying notes and independent auditor's report should be read in conjunction with the supplemental schedules.